| Summary: | <i>Background</i>. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with <i>BRAF</i>-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impact of anti-angiogenics in patients with pre-treated <i>BRAF</i>-mutant CRC. <i>Methods.</i> We monitored patients in randomized, controlled studies who had advanced CRC and were undergoing second-line chemotherapy in addition to utilizing Bevacizumab, Ramucirumab or Aflibercept treatments. These data were pooled together with the data and results of <i>BRAF</i>-mutant patients enrolled in two phase III trials (TRIBE and TRIBE-2 study), who had been treated with second-line treatment both with or without Bevacizumab. Overall survival (OS), in relation to <i>BRAF</i> mutational status, was the primary focus. <i>Results</i>. Pooled analysis included 129 patients. Anti-angiogenics were found to have a significant advantage over the placebo in terms of OS (HR 0.50, 95%CI 0.29–0.85) (<i>p</i> = 0.01). <i>Conclusions</i>. Our pooled analysis confirms the efficacy of anti-angiogenics in pre-treated <i>BRAF</i>-mutant CRC, establishing the combination of chemotherapy plus Bevacizumab or Ramucirumab or Aflibercept as a valid treatment option.
|
|---|